Abstract

ObjectiveTo collate and evaluate the current literature reporting the prevalence and incidence of hypoglycaemia in population based studies of type 2 diabetes.Research Design and MethodsMedline, Embase and Cochrane were searched up to February 2014 to identify population based studies reporting the proportion of people with type 2 diabetes experiencing hypoglycaemia or rate of events experienced. Two reviewers independently screened studies for eligibility and extracted data for included studies. Random effects meta-analyses were carried out to calculate the prevalence and incidence of hypoglycaemia.Results46 studies (n = 532,542) met the inclusion criteria. Prevalence of hypoglycaemia was 45% (95%CI 0.34,0.57) for mild/moderate and 6% (95%CI, 0.05,0.07) for severe. Incidence of hypoglycaemic episodes per person-year for mild/moderate and for severe was 19 (95%CI 0.00, 51.08) and 0.80 (95%CI 0.00,2.15), respectively. Hypoglycaemia was prevalent amongst those on insulin; for mild/moderate episodes the prevalence was 50% and incidence 23 events per person-year, and for severe episodes the prevalence was 21% and incidence 1 event per person-year. For treatment regimes that included a sulphonylurea, mild/moderate prevalence was 30% and incidence 2 events per person-year, and severe prevalence was 5% and incidence 0.01 events per person-year. A similar prevalence of 5% was found for treatment regimes that did not include sulphonylureas.ConclusionsCurrent evidence shows hypoglycaemia is considerably prevalent amongst people with type 2 diabetes, particularly for those on insulin, yet still fairly common for other treatment regimens. This highlights the subsequent need for educational interventions and individualisation of therapies to reduce the risk of hypoglycaemia.

Highlights

  • Hypoglycaemia in type 2 diabetes is associated with a considerable cost and burden to the health service, with an estimated annual cost to the NHS of £39 million[1]

  • Current evidence shows hypoglycaemia is considerably prevalent amongst people with type 2 diabetes, for those on insulin, yet still fairly common for other treatment regimens

  • A recent meta-analysis revealed that intensive glycaemic control in people with type 2 diabetes can result in a 17% reduction in non-fatal myocardial infarction and a 15% reduction in coronary heart disease events [12]

Read more

Summary

Introduction

Hypoglycaemia in type 2 diabetes is associated with a considerable cost and burden to the health service, with an estimated annual cost to the NHS of £39 million[1]. In addition to the direct effects of hypoglycaemia, there may be a substantial indirect impact on serious long-term health consequences from medication non-adherence and purposeful hyperglycaemia, due to fear and avoidance of hypoglycaemia [8]. In order to avoid long-term complications of type 2 diabetes, emphasis is placed on improving blood glucose control [9,10,11]. To help achieve tight glycaemic control, people with type 2 diabetes are frequently placed on intensive treatment regimens, including earlier initiation of insulin. Intensive regimens and tighter glycaemic control have been shown to increase the risk of hypoglycaemia[13,14,15]. Newer therapies and more treatment combinations, are increasingly becoming available, with the aim of maximising glucose control without the increased risk of hypoglycaemia[9, 16]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call